131 related articles for article (PubMed ID: 31323075)
1. Mathematical modeling of HIV-1 transmission risk from condomless anal intercourse in HIV-infected MSM by the type of initial ART.
Berenguer J; Parrondo J; Landovitz RJ
PLoS One; 2019; 14(7):e0219802. PubMed ID: 31323075
[TBL] [Abstract][Full Text] [Related]
2. Quantifying the reduction in sexual transmission of HIV-1 among MSM by early initiation of ART: A mathematical model.
Berenguer J; Parrondo J; Landovitz RJ
PLoS One; 2020; 15(7):e0236032. PubMed ID: 32687492
[TBL] [Abstract][Full Text] [Related]
3. Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients.
Curtis L; Nichols G; Stainsby C; Lim J; Aylott A; Wynne B; Clark A; Bloch M; Maechler G; Martin-Carpenter L; Raffi F; Min S
HIV Clin Trials; 2014; 15(5):199-208. PubMed ID: 25350958
[TBL] [Abstract][Full Text] [Related]
4. Integrase Inhibitor-Based Antiretroviral Therapy Among Women Living with HIV: Data from the OPERA Cohort.
Fusco J; Henegar C; Quinlivan EB; Vannappagari V; Aboud M; Smith K; Fusco G
Curr HIV Res; 2019; 17(4):266-276. PubMed ID: 31560291
[TBL] [Abstract][Full Text] [Related]
5. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
Dugdale CM; Ciaranello AL; Bekker LG; Stern ME; Myer L; Wood R; Sax PE; Abrams EJ; Freedberg KA; Walensky RP
Ann Intern Med; 2019 May; 170(9):614-625. PubMed ID: 30934067
[TBL] [Abstract][Full Text] [Related]
6. Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study.
Mills AM; Brunet L; Fusco JS; Wohlfeiler MB; Garris CP; Oglesby AK; Mrus JM; Lackey PC; Fusco GP
Infect Dis Ther; 2020 Mar; 9(1):41-52. PubMed ID: 31701370
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia.
Tremblay G; Chounta V; Piercy J; Holbrook T; Garib SA; Bukin EK; Punekar YS
Value Health Reg Issues; 2018 Sep; 16():74-80. PubMed ID: 30296624
[TBL] [Abstract][Full Text] [Related]
8. Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort.
d'Arminio Monforte A; Lorenzini P; Cozzi-Lepri A; Mussini C; Castagna A; Baldelli F; Puoti M; Vichi F; Maddaloni A; Lo Caputo S; Gianotti N; Antinori A;
HIV Clin Trials; 2018 Apr; 19(2):52-60. PubMed ID: 29493419
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
Moreno Guillen S; Losa García JE; Berenguer Berenguer J; Martínez Sesmero JM; Cenoz Gomis S; Graefenhain R; Lopez Sanchez-Cambronero D; Parrondo Garcia FJ
Farm Hosp; 2017 Sep; 41(5):601-610. PubMed ID: 28847249
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis.
Snedecor SJ; Radford M; Kratochvil D; Grove R; Punekar YS
BMC Infect Dis; 2019 May; 19(1):484. PubMed ID: 31146698
[TBL] [Abstract][Full Text] [Related]
11. Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials.
Jiang J; Xu X; Guo W; Su J; Huang J; Liang B; Chen H; Zang N; Liao Y; Ye L; Liang H
AIDS Res Ther; 2016; 13(1):30. PubMed ID: 27617024
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients.
Restelli U; Rizzardini G; Antinori A; Lazzarin A; Bonfanti M; Bonfanti P; Croce D
Ther Clin Risk Manag; 2017; 13():787-797. PubMed ID: 28721059
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of efavirenz, protease inhibitors, and raltegravir-based regimens as first-line treatment for HIV-infected adults: a mixed treatment comparison.
Vieira MC; Kumar RN; Jansen JP
HIV Clin Trials; 2011; 12(4):175-89. PubMed ID: 22044854
[TBL] [Abstract][Full Text] [Related]
14. Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
Rutherford GW; Horvath H
PLoS One; 2016; 11(10):e0162775. PubMed ID: 27736859
[TBL] [Abstract][Full Text] [Related]
15. HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen.
Karris MY; Jain S; Day TR; Pérez-Santiago J; Goicoechea M; Dubé MP; Sun X; Spina C; Daar ES; Haubrich RH; Morris S;
HIV Clin Trials; 2017 Mar; 18(2):67-74. PubMed ID: 28134057
[TBL] [Abstract][Full Text] [Related]
16. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO.
Molina JM; Clotet B; van Lunzen J; Lazzarin A; Cavassini M; Henry K; Kulagin V; Givens N; Brennan C; de Oliveira CF
J Int AIDS Soc; 2014; 17(4 Suppl 3):19490. PubMed ID: 25393999
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
Madeddu G; Rusconi S; Cozzi-Lepri A; Di Giambenedetto S; Bonora S; Carbone A; De Luca A; Gianotti N; Di Biagio A; Antinori A;
Infection; 2017 Aug; 45(4):521-528. PubMed ID: 28477212
[TBL] [Abstract][Full Text] [Related]
18. Estimating the Impact of Earlier ART Initiation and Increased Testing Coverage on HIV Transmission among Men Who Have Sex with Men in Mexico using a Mathematical Model.
Caro-Vega Y; del Rio C; Lima VD; Lopez-Cervantes M; Crabtree-Ramirez B; Bautista-Arredondo S; Colchero MA; Sierra-Madero J
PLoS One; 2015; 10(8):e0136534. PubMed ID: 26302044
[TBL] [Abstract][Full Text] [Related]
19. Acute HIV infection detection and immediate treatment estimated to reduce transmission by 89% among men who have sex with men in Bangkok.
Kroon EDMB; Phanuphak N; Shattock AJ; Fletcher JLK; Pinyakorn S; Chomchey N; Akapirat S; de Souza MS; Robb ML; Kim JH; van Griensven F; Ananworanich J; Wilson DP
J Int AIDS Soc; 2017 Jun; 20(1):21708. PubMed ID: 28691441
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France.
Pialoux G; Marcelin AG; Despiégel N; Espinas C; Cawston H; Finkielsztejn L; Laurisse A; Aubin C
PLoS One; 2015; 10(12):e0145885. PubMed ID: 26714188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
